Resubmission: Latent Class Trajectory Analysis in the OHTS Study
重新提交:OHTS 研究中的潜在类别轨迹分析
基本信息
- 批准号:10540153
- 负责人:
- 金额:$ 19.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAddressAffectAfrican American populationAfrican ancestryAmericanBlindnessCancer PatientCharacteristicsClassificationComputer softwareDataData SetDiagnosticDisease ProgressionEquilibriumEvaluation StudiesEventEyeGlaucomaGrowthHeterogeneityIncidenceInstitutesJointsLassoLettersLongitudinal StudiesLongitudinal trendsMalignant neoplasm of prostateMeasuresMedicalMethodsModelingOcular HypertensionOphthalmologyOutcomeParticipantPatientsPatternPharmaceutical PreparationsPhasePrimary Open Angle GlaucomaPrincipal Component AnalysisProstate-Specific AntigenPublic HealthQuality of lifeRadiation therapyResearch PersonnelRisk FactorsSpecific qualifier valueStructureTestingTimeTime trendUnited StatesVisionVisual FieldsWorkagedaggressive therapybasecostefficacy evaluationevidence basefollow-uphigh riskhypertension treatmentindividual variationinnovationinterestocular hypotensiveovertreatmentpatient subsetsprecision medicinepreventrandomized trialside effectsoftware developmentunnecessary treatmentuser-friendly
项目摘要
The Ocular Hypertension Treatment Study (OHTS) is a longitudinal study that tested whether topical ocular
hypotensive medication delays or prevents the onset of primary open-angle glaucoma (POAG). Characterizing
the longitudinal trajectory of visual field change and the effect of risk factors on the trajectory has high public
health significance. The progression of visual loss varies substantially from patient to patient. Therefore, it is
important to identify patients who are more likely to progress rapidly to prevent irreversible loss of visual
function. On the other hand, for patients whose glaucoma remains stable, over-treatment should be avoided to
reduce costs, side-effects, and inconvenience. For example, in OHTS, it would be of interest to classify the
trajectories into several groups with different rates of progression. In this proposal we will employ the latent
class mixed model (LCMM) to characterize the heterogeneity in the trajectory of visual field change. LCMM is a
data-driven classification approach, without pre-specifying the cut-point of each latent class as in other models.
Furthermore, LCMM is very comprehensive in that it includes several commonly used approaches as special
cases. We will extend the LCMM to address a number of challenging issues in modeling visual field trajectory
in OHTS: (1) develop a latent class joint model of mean deviation (MD, a quantitative measure of vision loss in
the visual field) trajectory to predict time to POAG; (2) use the (sparse group) Lasso method for variable
selection to achieve a proper balance between accuracy and efficiency; (3) jointly model of MD and other
measures of disease progression prior to POAG conversion, e.g., pattern standard deviation trajectories
simultaneously to predict time of POAG; (4) consider pointwise regression of visual field using functional
principal component analysis. Our extensions to LCMM will better capture individual heterogeneity in the
temporal trends of mean deviation and facilitate evidence-based precision medicine in glaucoma, in
ophthalmology, and other medical conditions.
高眼压治疗研究(OHTS)是一项纵向研究,
药物治疗可延迟或预防原发性开角型青光眼(POAG)的发作。表征
视野变化的纵向轨迹和危险因素对轨迹的影响具有较高的公信力。
健康意义。视力丧失的进展因患者而异。因此有
重要的是识别更有可能快速进展的患者,以防止不可逆的视力丧失。
功能另一方面,对于青光眼保持稳定的患者,应避免过度治疗,
降低成本、副作用和不便。例如,在OHTS中,将感兴趣的是将
以不同的发展速度分成几组。在这个建议中,我们将使用潜在的
类混合模型(LCMM)来表征视野变化轨迹的异质性。LCMM是一个
数据驱动的分类方法,而不预先指定每个潜在类在其他模型中的临界点。
此外,LCMM是非常全面的,因为它包括了几个常用的方法,
例我们将扩展LCMM来解决一些具有挑战性的问题,在建模视野轨迹
在OHTS中:(1)开发平均偏差(MD,一种视觉损失的定量测量,
(2)使用(稀疏组)Lasso方法进行变量分析,
选择以实现准确性和效率之间的适当平衡;(3)MD与其他模型的联合模型
POAG转换前的疾病进展指标,例如,模式标准差轨迹
同时预测POAG的时间;(4)用泛函分析方法考虑视野逐点回归
主成分分析我们对LCMM的扩展将更好地捕捉
平均偏差时间趋势和促进青光眼的循证精确医学,
眼科和其他医疗条件。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MAE O GORDON其他文献
MAE O GORDON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MAE O GORDON', 18)}}的其他基金
Long-Term Quality of Life in the Ocular Hypertension Treatment Study Cohort
高眼压治疗研究队列的长期生活质量
- 批准号:
10667711 - 财政年份:2023
- 资助金额:
$ 19.65万 - 项目类别:
Resubmission: Latent Class Trajectory Analysis in the OHTS Study
重新提交:OHTS 研究中的潜在类别轨迹分析
- 批准号:
10675764 - 财政年份:2022
- 资助金额:
$ 19.65万 - 项目类别:
Innovative Analytical Methods for Repeated Measures in the OHTS Study
OHTS 研究中重复测量的创新分析方法
- 批准号:
10219276 - 财政年份:2020
- 资助金额:
$ 19.65万 - 项目类别:
Reducing Adeno-Viral Patient Infected Days: Secondary Analyses
减少腺病毒患者感染天数:二次分析
- 批准号:
9809154 - 财政年份:2019
- 资助金额:
$ 19.65万 - 项目类别:
Ocular Hypertension Treatment Study 20-Year Follow-up: Clinical Center Grant
高眼压治疗研究 20 年随访:临床中心资助
- 批准号:
9316638 - 财政年份:2015
- 资助金额:
$ 19.65万 - 项目类别:
REDUCING ADENOVIRAL PATIENT-INFECTED DAYS (RAPID)
减少腺病毒患者感染天数(快速)
- 批准号:
8824082 - 财政年份:2015
- 资助金额:
$ 19.65万 - 项目类别:
Ocular Hypertension Treatment Study 20-Year Follow-up: Clinical Center Grant
高眼压治疗研究 20 年随访:临床中心资助
- 批准号:
9755439 - 财政年份:2015
- 资助金额:
$ 19.65万 - 项目类别:
Ocular Hypertension Treatment Study 20-Year Follow-up: Coordinating Center Grant
高眼压治疗研究 20 年随访:协调中心拨款
- 批准号:
9755440 - 财政年份:2015
- 资助金额:
$ 19.65万 - 项目类别:
Ocular Hypertension Treatment Study 20-Year Follow-up: Coordinating Center Grant
高眼压治疗研究 20 年随访:协调中心拨款
- 批准号:
9316636 - 财政年份:2015
- 资助金额:
$ 19.65万 - 项目类别:
REDUCING ADENOVIRAL PATIENT-INFECTED DAYS (RAPID)
减少腺病毒患者感染天数(快速)
- 批准号:
9543746 - 财政年份:2015
- 资助金额:
$ 19.65万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 19.65万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 19.65万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 19.65万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 19.65万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 19.65万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 19.65万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 19.65万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 19.65万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 19.65万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 19.65万 - 项目类别:
Research Grant














{{item.name}}会员




